Ivermectin is an endectocide belonging to the macrocyclic lactone class, commonly used in dogs as a heartworm preventative and for the treatment of several external and internal parasite infections. Among the analytical methods for ivermectin determination in plasma available in literature, many require a laborious clean-up step on SPE cartridge, and use fluorescence detection instead of the more reliable mass spectrometry. In the context of a project aimed at its pharmacokinetic evaluation in this species, a liquid chromatography-tandem mass spectrometry method for the determination of ivermectin in dog plasma was developed and validated, using blank plasma provided by a local canine blood transfusion service. Samples underwent a quick liquid-liquid extraction before analysis in the LC-MS/MS system, operating in selected reaction monitoring (SRM) mode. The method provided satisfactory linearity (R 2 >0.99), accuracy (bias <3%) and precision (CV <10%) over the 0.5-20.0 ng/mL range. This is to our knowledge the first validated LC-MS/MS method for ivermectin determination in dog plasma. Sample preparation is simple, rapid and inexpensive, without compromising sensitivity. The modest amount of plasma required makes the proposed technique suitable for pharmacokinetic studies also in small dogs.
Specifications

Method details
A method was validated for the determination of ivermectin (IVM) in dog plasma, using high performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS). Blank plasma samples were provided by a local canine blood transfusion service. The extraction procedure is rapid and simple, without requiring a SPE purification step, and allows the determination of IVM at levels as low as 0.5 ng/mL. The low volume of sample needed makes this approach suitable for pharmacokinetic studies also in small size dogs. The proposed technique has already been successfully employed to study IVM pharmacokinetics within a drug approval process, in which measured concentrations reached a maximum of 4.66 ng/mL and fell between the LLOQ and the LOD only at the final timepoints at the end of the elimination phase.
Materials
Ivermectin chemical reference substance (CRS) was supplied by the European Directorate for the Quality of Medicines and HealthCare (EDQM).
Sample Preparation
1 After thawing at room temperature, transfer 0.5 mL aliquots of each dog plasma sample into a 10 mL conical-bottomed polypropylene test tube. 2 Add 4 mL of acetonitrile (HPLC grade). 3 Add 2 mL of n-hexane (HPLC grade). 4 Agitate on vortex mixer for 10 min. 5 Centrifuge for 10 min at 1500 Âg at 5 C. 6 Transfer 4 mL of the lower phase into a new 10 mL conical-bottomed polypropylene test tube. 7 Evaporate under gentle nitrogen stream at 70 C. 8 Dissolve the dry residue with 0.2 mL of dilution phase, consisting of a methanol:water (50:50, v/v) solution containing 5 mM ammonium formate and 0.1% formic acid. 9 Agitate on vortex mixer for 5 min. 10 Place into an ultrasonic bath for 6 min. 11 Agitate on vortex mixer for 5 min. 12 Centrifuge for 5 min at 1500 Âg.
13 Filter through a 0.22 mm DURAPORE 1 PVDF syringe filter into a LC vial.
LC-MS/MS conditions
The LC system was an Agilent 1290 pump, equipped with autosampler and thermostated column compartment. Chromatographic separation was achieved on an Agilent Zorbax RRHD Eclipse Plus C18 column (1.8 mm, 2.1 Â 50 mm) combined with a guard column (1.8 mm, 2.1 Â 5 mm) of the same phase.
The column temperature was maintained at 40 C and the flow rate was 0. 
Method validation
The proposed method was validated in accordance with the European guidelines [1] . The specificity was confirmed by the absence of interfering compounds at the specific retention time of the analyte in the chromatograms obtained from blank plasma samples.
Matrix-matched calibration curves (six levels: 0.5, 1.0, 2.5, 5.0, 10.0 and 20.0 ng/mL) were freshly prepared during different days to evaluate the linearity of the method. Peak areas were plotted against their concentrations applying a "no weighting" linear regression model, obtaining satisfactory coefficients of correlation (R 2 >0.99). An example of the typical calibration curve is shown in Fig. 2 . The homogeneity of variance (homoscedasticity) and the regression model significance over the calibration range were assessed by using the Cochran test and the analyses of variance Lack of Fit test, respectively. The lower limit of quantification (LLOQ) of the method, corresponding to the lowest concentration with signal to noise (S/N) ratio >10 and acceptable precision and accuracy, was 0.5 ng/ mL. The limit of detection (LOD), corresponding to the lowest concentration with signal to noise (S/N) ratio >3, was 0.2 ng/mL. Accuracy and precision (intra-and inter-day) were tested by spiking blank plasma samples at three different concentrations (0.5, 1.0 and 20 ng/mL) in sextuplicate, and in three different days. The analysis of these QC samples proved the good accuracy (percentage difference always lower than AE3%) and precision (intra-and inter-day CV% always below AE10%) of the method (Table 1 ). The recovery was tested at two different concentrations within the validation range (0.5 and 5 ng/mL), resulting always >80%. Analyte stability was tested in solvent, fortified samples and sample extracts. Ivermectin was stable in solvent (methanol) at 2-8 C after 31 days, as confirmed by areas variation below AE10% compared to day 0. Stability of IVM in fortified samples was evaluated in triplicate at the lowest and highest levels of the validation range, resulting stable (percentage difference always below AE15%) within 6 h at room temperature, 24 h at 2-8 C, 49 days at À15 and À70 C, and following three freeze/thaw cycles at À15 and À70 C. Sample extracts (fortified at 0.5 and 20.0 ng/mL, in triplicate) were stable within 24 h after preparation when stored in amber vials at room temperature in the autosampler.
To evaluate the robustness of the method (defined as a measure of its capacity to remain unaffected by small but deliberate variations) different parameters have been observed and modified individually. Results demonstrated that variations of the volume of the extraction solvent (AE2.5%), of the composition of the mobile phase (AE2%) and of the collision energy (AE2%) do not have effects on the response of the analyte.
Additional information
Background
Ivermectin, an endectocide belonging to the macrocyclic lactone class, is commonly used in dogs as a heartworm preventative, and for the treatment of certain types of external and internal parasite infections. Ivermectin is a mixture of homologues comprising not less than 80% of 22,23-dihydroavermectin B1a and not more than 20% of 22,23-dihydroavermectin B1b. Effective dosages of ivermectin in dogs are very low, and therefore also its plasma concentrations. In order to study the pharmacokinetics of IVM, a sensitive and reliable method for its quantification in canine plasma is therefore necessary. Most of the existing methods in literature require a purification step on solid phase extraction (SPE) cartridge [2] [3] [4] , which is laborious, time consuming and expensive if compared to the quick liquid-liquid extraction here described. For these reasons, the proposed protocol might result preferable in PK studies, where large sets of samples must be processed. In addition, while liquid chromatography-fluorescence detection was used for ivermectin determination in previous studies on Table 1 Intraday and interday accuracy (D% = percentage difference between the experimental and theoretical values) and precision (CV %) for IVM (ivermectin), calculated on data obtained analyzing QC (quality control) samples prepared in three different days (total n = 54). dog plasma [5] [6] [7] , no other methods using LC-MS/MS are available to date. The use of a triple quadrupole instrument operating in selected reaction monitoring mode (SRM) grants unmatched specificity, and at the same time allows to perform only little sample preparation without affecting the high sensitivity provided.
